Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered ...

The Somerset facility also houses Catalent’s corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new location.

Oct 14 (Reuters) - Catalent (CTLT.N), opens new tab has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug ...

Financial details of the agreement, which is expected to close in early 2025, have not been disclosed. The Somerset facility also houses Catalent’s corporate headquarters, which in the ...